ADVERTISEMENT

Conference Report

ERS 2022 — Vilobelimab shows promise against severe COVID-19

Drishti Agarwal   |   09 September 2022

Takeaway

  • Vilobelimab leads to a 23.9% relative reduction in 28-day all-cause mortality compared with placebo.

Severe COVID-19 manifests in widespread complement activation in the lungs and kidneys, with increased levels of C5a and C5b. C5a, a potent anaphylatoxin, activates the coagulation system and may contribute to the development of acute...

          

November Challenge

Ends in 1d 5h
left
right

Topic Challenges

left
right